THE ROLE OF INTERLEUKIN - 1 IN POSTPRANDIAL SOMNOLENCE IN  DUHOK CITY, KURDISTAN REGION OF IRAQ

Farsat Saeed Saadi; BLAND BAYAR KHALEEL

Farsat Saeed Saadi Ministry of Health - Kurdistan Region of Iraq
BLAND BAYAR KHALEEL Diabetologist, Azadi Teaching Hospital, Duhok Governorate.

Keywords: Interleukin-1, Postprandial Somnolence, Inflammation, Stanford Sleepiness Scale

Abstract

https://doi.org/10.31386/dmj.2025.19.1.3

Abstract

Background: The number of patients with chronic kidney disease and those requiring dialysis is increasing markedly and can be considered as a major public health challenges. The current study aims to report on the risk factors of chronic kidney injury among diabetic and non-diabetic hemodialysis patients in Duhok Governorate, Kurdistan Region of Iraq.

Methods: This is a cross-sectional study conducted in facilities that provide dialysis treatment in Duhok province, Kurdistan Region of Iraq. A total of 171 registered cases who diagnosed as a chronic renal failure requiring maintenance hemodialysis treatment were included.

Results: The most common age group having chronic kidney injury was 55-69 years old. The results showed that most common factors were DM and hypertension. High creatinine level group were those aged 40-69 years and patients without DM show higher frequency of high S. Creatinine level. S. Creatinine was higher among non-controlled diabetic patients.

Conclusions: Proper evaluation and screening of risk factors, and appropriate intervention and treatment of underlying causes, and regular follow up is needed to reduce the overall cost and economic burden and to minimize the consequences and improve the prognosis of patients with chronic kidney injury especially those with diabetes mellitus and hypertension.

Downloads

Download data is not yet available.

References

1-Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6(3):158-66.
2-Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The role of interleukin-1 in general pathology. Inflamm Regener. 2019;39,12.
3-Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12:14–24.
4-Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;14;328(2):106-13.
5-Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;12;39(6):1003-18.
6-Lehrskov LL, Dorph E, Widmer AM, Hepprich M, Siegenthaler J, Timper K, et al. The role of IL-1 in postprandial fatigue. Mol Metab. 2018;12:107-112.
7-Roerink ME, Van Der Schaaf ME, Dinarello CA, Knoop H, Van Der Meer JWM. Interleukin-1 as a mediator of fatigue in disease: a narrative review. Journal of Neuroinflammation. 2017;14:1–21.
8-Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience. 2008;9:46–56.
9-Fang J, Wang Y, Krueger JM. Effects of interleukin-1 beta on sleep are mediated by the type I receptor. Am J Physiol. 1998;274(3):R655-60.
10-Wells AS, Read NW, Idzikowski C, Jones J. Effects of meals on objective and subjective measures of daytime sleepiness. J Appl Physiol (1985).1998;84(2):507-15.
11-Opp MR, Krueger JM. Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol. 1991;260(2Pt2):R453-7.
12-Litmanovich A, Khazim K, Cohen I. The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice. Oncol Ther. 2018;6:109–127.
13-Szekely Y, Arbel Y. A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?Cardiol Ther. 2018;7:25–44.
14-Dinarello CA. The role of interleukin-1 in host responses to infectious diseases. Infect Agents Dis. 1992;1(5):227-36.
15-Mrak RE, Griffin WS. Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol. 2000;59(6):471-6.
16-Rodenstein D. What is this thing called somnolence?. European Respiratory Journal. 2011;38:7-8.
17-Jewett KA, Krueger JM. Humoral sleep regulation; interleukin-1 and tumor necrosis factor. Vitam Horm. 2012;89:241-57.
18-TECAN. Interleukin-1beta (IL-1b) High Sensitivity ELISA. Switzerland. Tecan Trading AG [Cited July. 2023] Available from https://ibl-international.com/en/
19-Hoddes E, Zarcone V, Smythe H, Phillips R, Dement W.C. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431e436.
20-Shahid A, Shen J, Shapiro C.M. Measurements of sleepiness and fatigue. Journal of Psychosomatic Research. 2010;69:81e89.
21-Berry R. Subjective and Objective Measures of Daytime Sleepiness, Fundamentals of Sleep Medicine, W.B. Saunders. 2012;14:219-235.
22-Vaillant AAJ, Qurie A. Interleukin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023; PMID: 29763015.
23-Boraschi D. What Is IL-1 for? The Functions of Interleukin-1 Across Evolution. Front.Immunol. 2022;13:872155.
24-Murphy KR, Deshpande SA, Yurgel ME, Quinn JP, Weissbach JL, Keene AC, et al. Postprandial sleep mechanics in Drosophila. Elife. 2016;22;5:e19334.
25-Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 19861;163(6):1433-50.
26-Krueger JM. The role of cytokines in sleep regulation. Curr Pharm Des. 2008;14(32):3408-16.
27-Ghanbari M, Maragheh SM, Aghazadeh A, Mehrjuyan SR, Hussen BM, Shadbad MA, et al. Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies, International Immunopharmacology. 2021;96,107765,
28-Frühbeck G, Catalán V, Ramírez B, Valentí V, Becerril S, Rodríguez A, et al. Serum Levels of IL-1 RA Increase with Obesity and Type 2 Diabetes in Relation to Adipose Tissue Dysfunction and are Reduced After Bariatric Surgery in Parallel to Adiposity. J Inflamm Res. 2022;24;15:1331-1345.
29-Patel SR, Zhu X, Storfer-Isser A, Mehra R, Jenny NS, Tracy R, et al. Sleep duration and biomarkers of inflammation. SLEEP. 2009;32(2):200–204.